Genzyme (GENZ) Presents Preliminary Phase 2 Results of Clolar(R)
More News related to GENZ
- David Moenning’s Daily State of the Markets: 6/26
- Goldman Sachs Lowers Price Target On Genzyme (GENZ); Maintains Sell
- Genzyme Reports Progress Related to Allston Plant
- RBC Capital Initiates Coverage on Genzyme (GENZ) with an Outperform
- Baird Is a Buyer of BioMarin (BMRN) On Genzyme-Related Weakness
More News related to Corporate News
- Argon ST (STST) Awarded $8.3 Million to Provide U.S. Army Technology Enabler Development
- McKesson (MCK) Renews Pharmaceutical Distribution Agreement with CVS Caremark (CVS)
- Oclaro (OCLR) Closes Deal with Newport (NEWP) to Exchange Strategic Assets
- Cardinal Health (CAH) Renews Distribution Agreement with CVS Caremark (CVS) Through Mid-2013
- Caraco Pharmaceutical Laboratories (CPD) Announces Its Reducing Its Workforce By 350 Employees
Today at ASCO, Genzyme Corp. (Nasdaq: GENZ) reported preliminary data from a fully-enrolled pivotal, phase 2 study examining the safety and effectiveness of Clolar(R) as a single agent in previously untreated, older adult patients with acute myelogenous leukemia who are unlikely to benefit from conventional "7+3" anthracycline plus cytarabine-based induction chemotherapy.
Results from the CLASSIC-II clinical trial show that patients with unfavorable prognostic factors who received single agent clofarabine exhibited a 45% overall remission rate based on investigator assessment, with manageable treatment-related side effects. Importantly, the 30 day all-cause mortality, one of the secondary endpoints in this study, was only 9.6%, which compares favorably to existing treatment options.
Genzyme Corporation operates as a biotechnology company worldwide.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
